PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34002029-7	2021	Cells expressing NRAS and SETBP1 are sensitive to inhibitors of the MAPK pathway, and treatment with the MEK inhibitor trametinib conferred a survival benefit in a mouse model of NRAS/SETBP1-mutant disease.	trametinib	119-129	neuroblastoma ras oncogene	Mus musculus	17-21	
34002029-7	2021	Cells expressing NRAS and SETBP1 are sensitive to inhibitors of the MAPK pathway, and treatment with the MEK inhibitor trametinib conferred a survival benefit in a mouse model of NRAS/SETBP1-mutant disease.	trametinib	119-129	neuroblastoma ras oncogene	Mus musculus	179-183	
32576961-6	2020	The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS.	trametinib	71-81	neuroblastoma ras oncogene	Mus musculus	165-169	
32576961-8	2020	Thus, we identified the combination of azacitidine and trametinib as an effective treatment in NRAS-mutated CMML and propose its clinical development.	trametinib	55-65	neuroblastoma ras oncogene	Mus musculus	95-99	
26967478-6	2016	Reverse-phase protein array analysis of phospho-proteomic changes in mutant NRAS melanoma in response to trametinib indicated a compensatory increase in v-akt murine thymoma viral oncogene homolog signaling and decreased expression of mitogen-inducible gene 6 (MIG6), a negative regulator of epidermal growth factor receptor/v-erb-b2 erythroblastic leukemia viral oncogene homolog receptors.	trametinib	105-115	neuroblastoma ras oncogene	Mus musculus	76-80